Effect of Maraviroc on Metabolic Function in Obese Subjects (Phase I)

• Status: Completed
• Trial end date: 2012-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine the effect of maraviroc therapy in obese insulin resistant subjects on:

1. Plasma triglyceride concentration

2. Plasma HDL-cholesterol and LDL-cholesterol concentrations

3. Plasma markers of cardiometabolic risk and inflammation

• Phase: Phase 1
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Washington University School of Medicine
• Collaborator: Pfizer
• Treatments: Maraviroc

Criteria

Inclusion Criteria:

• obese (body mass index (BMI) between 30 and 45.9)

• increased plasma triglyceride concentrations (150-400 mg/dL)

Exclusion Criteria:

• active or previous infection with hepatitis B or C

• history of alcohol abuse

• current alcohol consumption (>20g/day)

• severe hypertriglyceridemia (>400 mg/dL)

• active peptic ulcer disease

• diabetes

• pregnant or lactating

• take statins, fibrates, niacin, moderate to strong Cyp3A4 inhibitors or inducers, or any other medication that might confound interpretation of the study results will be excluded.